A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week benralizumab dosing interval, discussion arose as to whether benralizumab should be administered or if treatment should be discontinued, due to the lack of experience with benralizumab in this situation. Severe broncho-obstruction developed, and the next injection of benralizumab was administered during ICU admission without detrimental symptoms. With this case report, we would like to share our experience with the safe administration of benralizumab during COVID-19 pneumonia, guiding doctors in future decision making.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251165PMC
http://dx.doi.org/10.1136/ejhpharm-2020-002660DOI Listing

Publication Analysis

Top Keywords

administration benralizumab
8
patient severe
8
severe asthma
8
admitted intensive
8
intensive care
8
care unit
8
covid-19 pneumonia
8
case report
8
benralizumab administered
8
benralizumab
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!